Red Cat (NASDAQ: RCAT) has recently received a number of price target changes and ratings updates:
- 10/8/2025 – Red Cat had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
- 10/4/2025 – Red Cat was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
- 10/3/2025 – Red Cat is now covered by analysts at Needham & Company LLC. They set a “buy” rating and a $17.00 price target on the stock.
- 10/3/2025 – Red Cat is now covered by analysts at Needham & Company LLC. They set a “buy” rating and a $17.00 price target on the stock.
- 10/2/2025 – Red Cat was upgraded by analysts at LADENBURG THALM/SH SH to a “strong-buy” rating.
- 9/27/2025 – Red Cat had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
Insider Activity
In other news, Director Christopher R. Moe sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $10.91, for a total transaction of $109,100.00. Following the sale, the director owned 53,073 shares of the company’s stock, valued at $579,026.43. This trade represents a 15.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have sold 86,833 shares of company stock worth $861,560. Company insiders own 15.30% of the company’s stock.
Red Cat Holdings, Inc engages in the provision of various products, services, and solutions to the drone industry. The company operates through two segments: Enterprise and Consumer. It built infrastructure to manages drone fleets and fly, and provide services remotely, navigate confined industrial interior spaces and dangerous military environment.
Further Reading
- Five stocks we like better than Red Cat
- Which Wall Street Analysts are the Most Accurate?
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- Want to Profit on the Downtrend? Downtrends, Explained.
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Trading Stocks: RSI and Why it’s Useful
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Red Cat Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Red Cat Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.